Department of Bioengineering, University of California at San Diego, La Jolla, CA 92093-0412, USA.
Drug Discov Today. 2013 Feb;18(3-4):116-27. doi: 10.1016/j.drudis.2012.09.003. Epub 2012 Sep 19.
A crucial question that must be addressed in the drug development process is whether the proposed therapeutic target will yield the desired effect in the clinical population. Pharmaceutical and biotechnology companies place a large investment on research and development, long before confirmatory data are available from human trials. Basic science has greatly expanded the computable knowledge of disease processes, both through the generation of large omics data sets and a compendium of studies assessing cellular and systemic responses to physiologic and pathophysiologic stimuli. Given inherent uncertainties in drug development, mechanistic systems models can better inform target selection and the decision process for advancing compounds through preclinical and clinical research.
在药物开发过程中，必须解决一个关键问题，即拟议的治疗靶点是否会在临床人群中产生预期的效果。制药和生物技术公司在获得来自人体试验的确认数据之前，会在研究和开发上投入大量资金。基础科学通过生成大型组学数据集和评估细胞和系统对生理和病理生理刺激的反应的综合研究，极大地扩展了疾病过程的可计算知识。鉴于药物开发中固有的不确定性，机制系统模型可以更好地为目标选择提供信息，并为通过临床前和临床研究推进化合物的决策过程提供信息。
